East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Brivaracetam Tablets, 50 mg and 100 mg. Aurobindo Pharma’s Brivaracetam Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), BRIVIACT® (brivaracetam) Tablets manufactured by UCB Inc.

Brivaracetam Tablets are indicated for:

• The treatment of partial-onset seizures in patients 4 years of age and older.